Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01103193
Other study ID # 2009/493
Secondary ID
Status Terminated
Phase Phase 4
First received March 19, 2010
Last updated May 7, 2012
Start date February 2010
Est. completion date May 2010

Study information

Verified date May 2012
Source University Hospital, Ghent
Contact n/a
Is FDA regulated No
Health authority Belgium: Federal Agency for Medicinal Products and Health ProductsBelgium: Institutional Review Board
Study type Interventional

Clinical Trial Summary

patients are allocated to one of the two study groups.

In both groups a mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol. In the second group remifentanil is injected in a fixed rate and sevoflurane is administered in a step up concentration.

During the study, at predefined times, we will assess different levels of sedation (OAA/S score) and the reaction on tetanic stimulation of the ulnar nerve, insertion of a laryngeal mask airway and laryngoscopy. In addition heart rate, SpO2 and capnography will be recorded continuously and non invasive bloodpressure will be recorded using a 1 minute interval time. Spectral entropy and BIS derived from the frontal EEG will be used to monitor clinical cerebral drug effect.

The null hypothesis is that remifentanil lowers the concentration of sevoflurane dissolved in a mixture of 60% nitrous oxide and 40% oxygen to (1) tolerate a specific stimulation and to (2) obtain a certain electroencephalographic parameter value and vice versa. Additionally the results of this study will be compared with a former interaction study of the same study group that did not involve nitrous oxide, in order to depict the shift in the response surface evoked by nitrous oxide.


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date May 2010
Est. primary completion date May 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- American Society of Anesthesia class I and II patients

- aged 18-60 years

- scheduled for surgery under general anesthesia.

Exclusion Criteria:

- Weight less than 70% or more than 130% of ideal body weight

- neurological disorder

- diseases involving the cardiovascular system, pulmonary disease, gastric diseases, endocrinological diseases

- recent use of psycho-active medication, including alcohol

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms

  • ASA Class I/II Patients Scheduled for Surgery Under General Anesthesia

Intervention

Drug:
remifentanil injected
mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol.
sevoflurane in step up concentration
of 60% nitrous oxide and 40% oxygen is administered through a face mask.remifentanil is injected in a fixed rate and sevoflurane is administered in a step up concentration.

Locations

Country Name City State
Belgium University Hospital Ghent Ghent

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Ghent

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary To investigate the pharmacodynamic interaction between nitrous oxide, sevoflurane and remifentanil The interaction is studied on response surfaces including several clinical endpoints: the observer assessment of alertness and sedation scale, the heart rate, pulse oximetry, blood pressure, EEG and the derived parameters from it: spectral entropy and BIS Every 12 minutes during induction and maintenance of anesthesia No